Ruth M Seeber

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8744072/publications.pdf

Version: 2024-02-01

23 papers 1,537 citations

471061 17 h-index 713013 21 g-index

23 all docs 23 docs citations

 $\begin{array}{c} 23 \\ times \ ranked \end{array}$

1996 citing authors

#	Article	IF	CITATIONS
1	Model for growth hormone receptor activation based on subunit rotation within a receptor dimer. Nature Structural and Molecular Biology, 2005, 12, 814-821.	3.6	345
2	Bioluminescence resonance energy transfer (BRET) for the real-time detection of protein-protein interactions. Nature Protocols, 2006 , 1 , $337-345$.	5 . 5	188
3	Constitutive and Agonist-dependent Homo-oligomerization of the Thyrotropin-releasing Hormone Receptor. Journal of Biological Chemistry, 2001, 276, 12736-12743.	1.6	171
4	$\hat{l}\pm\hat{v}^2$ 3 Integrin Interacts with the Transforming Growth Factor \hat{l}^2 (TGF \hat{l}^2) Type II Receptor to Potentiate the Proliferative Effects of TGF \hat{l}^2 1 in Living Human Lung Fibroblasts. Journal of Biological Chemistry, 2004, 279, 37726-37733.	1.6	95
5	Demonstration of Improvements to the Bioluminescence Resonance Energy Transfer (BRET) Technology for the Monitoring of G Protein–Coupled Receptors in Live Cells. Journal of Biomolecular Screening, 2008, 13, 888-898.	2.6	90
6	Plasma Leptin-Binding Activity and Hypothalamic Leptin Receptor Expression During Pregnancy and Lactation in the Rat1. Biology of Reproduction, 2002, 66, 1762-1767.	1.2	81
7	The Duffy Antigen/Receptor for Chemokines Exists in an Oligomeric Form in Living Cells and Functionally Antagonizes CCR5 Signaling through Hetero-Oligomerization. Molecular Pharmacology, 2008, 73, 1362-1370.	1.0	79
8	Homo- and Hetero-oligomerization of Thyrotropin-releasing Hormone (TRH) Receptor Subtypes. Journal of Biological Chemistry, 2002, 277, 50422-50430.	1.6	67
9	Heteromerization of angiotensin receptors changes trafficking and arrestin recruitment profiles. Cellular Signalling, 2011, 23, 1767-1776.	1.7	63
10	Transactivation of RAGE mediates angiotensin-induced inflammation and atherogenesis. Journal of Clinical Investigation, 2018, 129, 406-421.	3.9	59
11	Identification and Profiling of Novel $\hat{l}\pm 1$ A-Adrenoceptor-CXC Chemokine Receptor 2 Heteromer. Journal of Biological Chemistry, 2012, 287, 12952-12965.	1.6	49
12	Application of G Protein-Coupled Receptor-Heteromer Identification Technology to Monitor $\langle i \rangle$ 2 2 / 2 -Arrestin Recruitment to G Protein-Coupled Receptor Heteromers. Assay and Drug Development Technologies, 2011, 9, 21-30.	0.6	47
13	Cytoplasmic Terminus of Vacuolar Type Proton Pump Accessory Subunit Ac45 Is Required for Proper Interaction with V0 Domain Subunits and Efficient Osteoclastic Bone Resorption. Journal of Biological Chemistry, 2008, 283, 13194-13204.	1.6	41
14	Mutations of Vasopressin Receptor 2 Including Novel L312S Have Differential Effects on Trafficking. Molecular Endocrinology, 2016, 30, 889-904.	3.7	39
15	Biocompatibility of semiconducting AlGaN/GaN material with living cells. Sensors and Actuators B: Chemical, 2012, 169, 401-406.	4.0	28
16	Enhanced BRET technology for the monitoring of agonist-induced and agonist-independent interactions between GPCRs and \hat{l}^2 -arrestins. Frontiers in Endocrinology, 2010, 1, 12.	1.5	24
17	Characterization of Three Vasopressin Receptor 2 Variants: An Apparent Polymorphism (V266A) and Two Loss-of-Function Mutations (R181C and M311V). PLoS ONE, 2013, 8, e65885.	1.1	24
18	Molecular determinants of orexin receptorâ€arrestinâ€abiquitin complex formation. British Journal of Pharmacology, 2014, 171, 364-374.	2.7	17

#	Article	IF	CITATIONS
19	Profiling Epidermal Growth Factor Receptor and Heregulin Receptor 3 Heteromerization Using Receptor Tyrosine Kinase Heteromer Investigation Technology. PLoS ONE, 2013, 8, e64672.	1.1	14
20	Helix I of \hat{I}^2 -Arrestin Is Involved in Postendocytic Trafficking but Is Not Required for Membrane Translocation, Receptor Binding, and Internalization. Molecular Pharmacology, 2005, 67, 375-382.	1.0	10
21	Cell growth and attachment to AlGaN surfaces for biosensor applications. , 2010, , .		2
22	Complex interactions between the angiotensin II type 1 receptor, the epidermal growth factor receptor and TRIO-dependent signaling partners. Biochemical Pharmacology, 2021, 188, 114521.	2.0	2
23	Novel Pharmacology Following Heteromerization of the Angiotensin II Type 2 Receptor and the Bradykinin Type 2 Receptor. Frontiers in Endocrinology, 2022, $13,\ldots$	1.5	2